N-Cadherin mRNA Levels in Peripheral Blood Could Be a Potential Indicator of New Metastases in Breast Cancer: A Pilot Study.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Biomarkers, Tumor
Breast Neoplasms
/ diagnosis
Cadherins
/ genetics
Cell Line, Tumor
Cell-Free Nucleic Acids
Combined Modality Therapy
Epithelial-Mesenchymal Transition
/ genetics
Female
Gene Expression Regulation, Neoplastic
Humans
Middle Aged
Neoplasm Staging
Pilot Projects
Prognosis
RNA, Messenger
/ genetics
EMT
N-cadherin
biomarker
blood
breast cancer
eribulin
new metastasis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 Jan 2020
14 Jan 2020
Historique:
received:
04
01
2020
revised:
12
01
2020
accepted:
12
01
2020
entrez:
18
1
2020
pubmed:
18
1
2020
medline:
7
10
2020
Statut:
epublish
Résumé
There is growing evidence that patients with metastatic breast cancer whose disease progresses from a new metastasis (NM) have a worse prognosis than that of patients whose disease progresses from a pre-existing metastasis. The aim of this pilot study is to identify a blood biomarker predicting NM in breast cancer. The expression of epithelial (cytokeratin 18/19) or mesenchymal (plastin-3, vimentin, and N-cadherin) markers in the peripheral blood (PB) of recurrent breast cancer patients undergoing chemotherapy with eribulin or S-1 was measured over the course of treatment by RT-qPCR. The clinical significance of preoperative N-cadherin expression in the PB or tumor tissues of breast cancer patients undergoing curative surgery was assessed by RT-qPCR or using public datasets. Finally, N-cadherin expression in specific PB cell types was assessed by RT-qPCR. The expression levels of the mesenchymal markers N-cadherin and vimentin were high in the NM cases, whereas that of the epithelial marker cytokeratin 18 was high in the pre-existing metastasis cases. High preoperative N-cadherin expression in PB or tumor tissues was significantly associated with poor recurrence-free survival. N-cadherin was expressed mainly in polymorphonuclear leukocytes in PB. N-cadherin mRNA levels in blood may serve as a novel prognostic biomarker predicting NM, including recurrence, in breast cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
There is growing evidence that patients with metastatic breast cancer whose disease progresses from a new metastasis (NM) have a worse prognosis than that of patients whose disease progresses from a pre-existing metastasis. The aim of this pilot study is to identify a blood biomarker predicting NM in breast cancer.
METHODS
METHODS
The expression of epithelial (cytokeratin 18/19) or mesenchymal (plastin-3, vimentin, and N-cadherin) markers in the peripheral blood (PB) of recurrent breast cancer patients undergoing chemotherapy with eribulin or S-1 was measured over the course of treatment by RT-qPCR. The clinical significance of preoperative N-cadherin expression in the PB or tumor tissues of breast cancer patients undergoing curative surgery was assessed by RT-qPCR or using public datasets. Finally, N-cadherin expression in specific PB cell types was assessed by RT-qPCR.
RESULTS
RESULTS
The expression levels of the mesenchymal markers N-cadherin and vimentin were high in the NM cases, whereas that of the epithelial marker cytokeratin 18 was high in the pre-existing metastasis cases. High preoperative N-cadherin expression in PB or tumor tissues was significantly associated with poor recurrence-free survival. N-cadherin was expressed mainly in polymorphonuclear leukocytes in PB.
CONCLUSION
CONCLUSIONS
N-cadherin mRNA levels in blood may serve as a novel prognostic biomarker predicting NM, including recurrence, in breast cancer patients.
Identifiants
pubmed: 31947504
pii: ijms21020511
doi: 10.3390/ijms21020511
pmc: PMC7013704
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Cadherins
0
Cell-Free Nucleic Acids
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Society for the Promotion of Science
ID : JP16K07177, JP16K10543, JP16K19197, JP17K16454, JP17K16521, JP17K10593, and JP17K19608
Organisme : OITA Cancer Research Foundation
ID : none
Organisme : Daiwa Securities Health Foundation
ID : none
Organisme : Grant-in-Aid for Scientific Research on Innovative Areas
ID : 15H0912
Organisme : Priority Issue on Post-K computer
ID : (hp170227 and hp160219
Organisme : JSPS KAKENHI
ID : 15H05707
Organisme : Eli Lilly Japan K.K. Grant
ID : none
Organisme : Japanese Foundation for Multidisciplinary Treatment of Cancer
ID : none
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Cancer. 2014 Jul;50(10):1847-1853
pubmed: 24726734
Cancer Res. 2013 Apr 1;73(7):2059-69
pubmed: 23378342
Oncogene. 2011 Nov 17;30(46):4609-21
pubmed: 21643013
Lancet Oncol. 2016 Jan;17(1):90-8
pubmed: 26617202
Br J Haematol. 2013 May;161(4):499-507
pubmed: 23438504
Int J Mol Sci. 2018 Sep 21;19(10):
pubmed: 30248975
Mol Oncol. 2016 Mar;10(3):408-17
pubmed: 26899533
Eur J Cell Biol. 2016 Nov;95(11):415-426
pubmed: 27320194
Lancet. 2011 Mar 12;377(9769):914-23
pubmed: 21376385
J Transl Med. 2018 Mar 9;16(1):54
pubmed: 29523158
J Clin Oncol. 2015 Feb 20;33(6):594-601
pubmed: 25605862
Cancer Treat Rev. 2018 Nov;70:190-198
pubmed: 30243063
Anticancer Res. 2018 Aug;38(8):4515-4523
pubmed: 30061217
Br J Cancer. 1978 Dec;38(6):745-8
pubmed: 743491
Eur J Clin Invest. 2018 Apr;48(4):
pubmed: 29405291
Ann Oncol. 2016 Aug;27(8):1525-31
pubmed: 27177860
Ann Oncol. 2015 Aug;26(8):1533-46
pubmed: 25939896
Mol Cancer. 2017 Apr 14;16(1):80
pubmed: 28410618
Anticancer Res. 2018 Dec;38(12):6631-6638
pubmed: 30504371
J Transl Med. 2018 Oct 20;16(1):287
pubmed: 30342534
BMC Cancer. 2018 Oct 1;18(1):939
pubmed: 30285678
Oncotarget. 2017 Nov 21;8(64):107666-107677
pubmed: 29296196
Br J Cancer. 1996 Jun;73(12):1545-51
pubmed: 8664127
BMC Med Genomics. 2009 Apr 24;2:18
pubmed: 19393097
Int J Mol Sci. 2016 Aug 11;17(8):
pubmed: 27529216
Oncotarget. 2017 Aug 7;8(45):78598-78613
pubmed: 29108252
Dev Dyn. 2018 Mar;247(3):432-450
pubmed: 28407379
World J Surg Oncol. 2018 Aug 14;16(1):169
pubmed: 30107807
Br J Cancer. 2014 Mar 18;110(6):1497-505
pubmed: 24569463
Springerplus. 2014 Aug 08;3:417
pubmed: 25140293
J Clin Oncol. 2017 Oct 20;35(30):3433-3439
pubmed: 28854066
Oncotarget. 2018 May 1;9(33):22986-23002
pubmed: 29796167
Annu Rev Biochem. 1990;59:237-52
pubmed: 2197976
Breast Cancer Res. 2015 Dec 09;17(1):150
pubmed: 27391598
Cancer. 1984 Nov 15;54(10):2237-42
pubmed: 6488142
Biomed Pharmacother. 2019 Oct;118:109320
pubmed: 31545265
Arch Surg. 1987 Nov;122(11):1303-6
pubmed: 3675194
Br J Cancer. 2015 Apr 28;112(9):1519-26
pubmed: 25880010
Clin Cancer Res. 2004 Sep 1;10(17):5702-7
pubmed: 15355896
Oncogene. 2004 Jun 10;23(27):4745-53
pubmed: 15122336
Curr Pharm Des. 2016;22(5):616-38
pubmed: 26825466